The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock List
ChartZero.com
ChartZero
Synageva BioPharma Corp (GEVA)

Synageva BioPharma is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. Co.'s pipeline programs are enzyme replacement therapies for lysosomal storage diseases (LSDs). Co.'s lead program, sebelipase alfa, is in global Phase 3 clinical investigation for the treatment of infants, children and adults with lysosomal acid lipase deficiency, a disease that causes morbidity and mortality. In addition, Co. has several other ongoing research programs at different stages of preclinical development, including SBC-103, another enzyme replacement therapy for an LSD known as mucopolysaccharidosis type IIIB.

Recommended for you: 25 S.A.F.E. Dividend Stocks
Company Name:  Synageva BioPharma Corp
Website:  www.synageva.com
Sector:  Biotechnology
Number of ETFs Holding GEVA:  24
Total Market Value Held by ETFs:  $85.51M
Total Market Capitalization:  $2.14B
% of Market Cap. Held by ETFs:  3.99%
September 20, 2014    10:01 PM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes



Strong Buy (3.67 out of 4)
80th percentile
(ranked higher than approx. 80% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Synageva BioPharma Corp (GEVA) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2014, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.